Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 355

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

Open access
Lee, Holly, Ahn, Sungwoo, Maity, Ranjan, Leblay, Noemie, Ziccheddu, Bachisio, Truger, Marietta, Chojnacka, Monika, Cirrincione, Anthony, Durante, Michael, Tilmont, Remi, Barakat, Elie, Poorebrahim, Mansour, Sinha, Sarthak, McIntyre, John, M.Y. Chan, Angela, Wilson, Holly, Kyman, Shari, Krishnan, Amrita, Landgren, Ola, Walter, Wencke, Meggendorfer, Manja, Haferlach, Claudia, Haferlach, Torsten, Einsele, Hermann, Kortüm, Martin K., Knop, Stefan, Alberge, Jean Baptiste, Rosenwald, Andreas, Keats, Jonathan J., Rasche, Leo, Maura, Francesco, Neri, Paola, Bahlis, Nizar J.·2023·Nature Medicine

Abstract

B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G-protein-coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T therapy. To examine the tumor-intrinsic factors that promote MM antigen escape, we performed combined bulk and single-cell whole-genome sequencing and copy number variation analysis of 30 patients treated with anti-BCMA and/or anti-GPRC5D CAR T/TCE therapy. In two cases, MM relapse post-TCE/CAR T therapy was driven by BCMA-negative clones harboring focal biallelic deletions at the TNFRSF17 locus at relapse or by selective expansion of pre-existing subclones with biallelic TNFRSF17 loss. In another five cases of relapse, newly detected, nontruncating, missense mutations or in-frame deletions in the extracellular domain of BCMA negated the efficacies of anti-BCMA TCE therapies, despite detectable surface BCMA protein expression. In the present study, we also report four cases of MM relapse with biallelic mutations of GPRC5D after anti-GPRC5D TCE therapy, including two cases with convergent evolution where multiple subclones lost GPRC5D through somatic events. Immunoselection of BCMA- or GPRC5D-negative or mutant clones is an important tumor-intrinsic driver of relapse post-targeted therapies. Mutational events on BCMA confer distinct sensitivities toward different anti-BCMA therapies, underscoring the importance of considering the tumor antigen landscape for optimal design and selection of targeted immunotherapies in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02491-5

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 355

Metadata

Authors
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M., Chojnacka, M., Cirrincione, A., Durante, M., Tilmont, R., Barakat, E., Poorebrahim, M., Sinha, S., McIntyre, J., M.Y. Chan, A., Wilson, H., Kyman, S., Krishnan, A., Landgren, O., Walter, W., Meggendorfer, M., Haferlach, C., Haferlach, T., Einsele, H., Kortüm, M. K., Knop, S., Alberge, J. B., Rosenwald, A., Keats, J. J., Rasche, L., Maura, F., Neri, P., & Bahlis, N. J.
Venue
Nature Medicine
Published
2023-08-31
Volume
29
Issue
9
Pages
2295-2306
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4386324983
Cited by
355
References
39
FWCI
63.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. https://app.cochat.ai/papers/10.1038/s41591-023-02491-5
The paper
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M., Chojnacka, M., Cirrincione, A., Durante, M., Tilmont, R., Barakat, E., Poorebrahim, M., Sinha, S., McIntyre, J., M.Y. Chan, A., Wilson, H., Kyman, S., Krishnan, A., Landgren, O., . . . Bahlis, N. J. (2023). Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nature Medicine. https://doi.org/10.1038/s41591-023-02491-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.